Business
Bone Biologics Announces Pricing of $5.0 Million Public Offering
BURLINGTON, Mass., June 27, 2025--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a pub
About this update from Bone Biologics Corp
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/5ff75858cf23e8b7d2d42772ec0ffd0b"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_A6aR9vRbuGPmS248kaOEQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5ff75858cf23e8b7d2d42772ec0ffd0b","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/YSwkI0DRdf2gzvTECbH9gA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/5ff75858cf23e8b7d2d42772ec0ffd0b","width":1024,"height":512}},"lazy":false},{"type":"text","content":"BURLINGTON, Mass., June 27, 2025--(BUSINESS WIRE)--Bone Biologics Corporation ("Bone Biologics" or the "Company") (Nasdaq: BBLG, BBLGW), a developer of orthobiologic products for spine fusion markets, today announced the pricing of its public offering of an aggregate of 1,250,000 shares of its common stock (or common stock equivalents in lieu thereof), Series D warrants to purchase up to 1,250,000 shares of common stock and Series E short-term warrants to purchase up to 1,250,000 shares of common stock, at a public offering price of $4.00 per share (or common stock equivalent in lieu thereof) and accompanying warrants. The Series D warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and will expire five years after the date of issuance, and the Series E short-term warrants will have an exercise price of $4.00 per share, will be exercisable immediately upon issuance and will expire 18 months after the date of issuance. The closing of the offering is expected to occur on or about June 30, 2025, subject to the satisfaction of customary closing conditions.","length":1139,"tagName":"p"},{"type":"text","content":"H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.","length":86,"tagName":"p"},{"type":"text","content":"Total gross proceeds to the Company from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be $5.0 million. The potential additional gross proceeds to the Company from the warrants, if fully-exercised on a cash basis, will be $10.0 mill...